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Ibukun M. Ogunade 3, Kyle R. McLeod 1 and David L. Harmon 1*
1Department of Animal and Food Sciences, University of Kentucky, Lexington, KY, United States, 2College of Veterinary
Medicine, Lincoln Memorial University, Harrogate, TN, United States, 3Division of Animal and Nutritional Science, West
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Despite the increased interest and widespread use of cannabidiol (CBD) in humans
and companion animals, much remains to be learned about its effects on health
and physiology. Metabolomics is a useful tool to evaluate changes in the health
status of animals and to analyze metabolic alterations caused by diet, disease, or
other factors. Thus, the purpose of this investigation was to evaluate the impact
of CBD supplementation on the canine plasma metabolome. Sixteen dogs (18.2
± 3.4 kg BW) were utilized in a completely randomized design with treatments
consisting of control and 4.5mg CBD/kg BW/d. After 21 d of treatment, blood was
collected ∼2 h after treat consumption. Plasma collected from samples was analyzed
using CIL/LC-MS-based untargeted metabolomics to analyze amine/phenol- and
carbonyl-containing metabolites. Metabolites that differed — fold change (FC) ≥ 1.2
or ≤ 0.83 and false discovery ratio (FDR) ≤ 0.05 — between the two treatments
were identified using a volcano plot. Biomarker analysis based on receiver operating
characteristic (ROC) curves was performed to identify biomarker candidates (area
under ROC ≥ 0.90) of the effects of CBD supplementation. Volcano plot analysis
revealed that 32 amine/phenol-containing metabolites and five carbonyl-containing
metabolites were differentially altered (FC ≥ 1.2 or ≤ 0.83, FDR ≤ 0.05) by CBD;
these metabolites are involved in the metabolism of amino acids, glucose, vitamins,
nucleotides, and hydroxycinnamic acid derivatives. Biomarker analysis identified 24
amine/phenol-containing metabolites and 1 carbonyl-containing metabolite as candidate
biomarkers of the effects of CBD (area under ROC ≥ 0.90; P < 0.01). Results of this
study indicate that 3 weeks of 4.5mg CBD/kg BW/d supplementation altered the canine
metabolome. Additional work is warranted to investigate the physiological relevance of
these changes.
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INTRODUCTION
Cannabidiol (CBD) is one of over 100 phytocannabinoids
produced by glandular trichomes of Cannabis sativa (1–
3). Cannabidiol has been proposed to induce a plethora of
beneficial health effects, including anxiolytic, antipsychotic, anti-
inflammatory, analgesia, and immunomodulatory effects (4, 5).
The wide range of potential therapeutic effects are thought
to be a result of multiple mechanisms of action on receptors
known to be a part of the endocannabinoid system [ECS; (6, 7)].
Due to the psychoactive effects caused by the action of 19-
tetrahydrocannabinol (THC) on the CB1 receptor, hemp and all
its products, including CBD, were classified as illegal, Schedule I
drugs under the Controlled Substances Act (CSA) in 1970 (8, 9).
This severely restricted access to CBD as well as the potential for
research into the effects of CBD on mammalian physiological
systems. As a result, there was little to no opportunity to
investigate the potential effects of CBD until industrial hemp was
removed from the CSA and CBDwas removed from the Schedule
I drug list in 2018 (10).
Despite the lack of research, public perception of the supposed
health benefits of CBD has led to a rapid expansion of the market
for industrial hemp-derived CBD products. In one survey of
over 1,100 dog owners, 79.8% said they had purchased hemp
or marijuana for their dogs for reasons such as pain relief,
relieving anxiety or noise phobia, and reduction of inflammation
(11). While this survey represents only a small portion of the
population, it does demonstrate favorable perceptions of pet
owners on the safety and efficacy of CBD use in pets. Yet despite
public opinion, there remains a substantial lack of scientific
literature to back these anecdotal claims, particularly regarding
potential effects of CBD on long-term health and safety, which
makes continued research into its potential benefits and risks all
the more essential.
Mass spectrometry-based metabolomics has been increasingly
used to assess the health and status of animals and to
analyze metabolic alterations caused by diet, disease, or other
factors (12–14). Targeted metabolomics can be used to quantify
defined groups of metabolites, whereas untargeted metabolomics
provides a comprehensive analysis of all measurable analytes in
a sample, including any unknowns (15, 16). In instances where
the specific metabolites of interest are unknown, untargeted
metabolomics can also be used to discover specific biomarkers
for later use in targeted metabolomics studies as well as pathway
analysis (17, 18). In recent years, chemical isotope labeling (CIL)
and liquid chromatography-mass spectrometry (LC-MS)-based
untargeted metabolomics has provided an opportunity to analyze
metabolites based on chemical groups, including metabolites
containing the amine/phenol chemical group (amine/phenol
metabolome) which are common intermediate products of
amino acid metabolism, and metabolites containing a carbonyl
group (carbonyl-metabolome) which common intermediate
products of energy metabolism (19).
To date, there has been no evaluation of the effect of
CBD on the canine metabolome. Therefore, the objective
of this exploratory study was to evaluate the impact of
CBD supplementation on the canine metabolome with the
underlying hypothesis that after 3 weeks of supplementation,
CBD would alter the canine metabolome compared with
control. This was accomplished through the use of untargeted
metabolomics and biomarker analysis of amine/phenol- and
carbonyl-containing metabolites.
MATERIALS AND METHODS
This study was approved by the Lincoln Memorial University
(LMU) institutional animal care and use committee (protocol
1911-RES) before the start of the study. All housing and
husbandry were provided in accordance with the AnimalWelfare
Act, the Guide for the Care and Use of Laboratory Animals (8th
ed.), and all applicable LMU protocols.
Subjects and Diets
Sixteen dogs (eight male, eight female, 9 months to 4 years of
age, 18.2 ± 3.4 kg BW) of various mixed breeds were received
from a local shelter for inclusion in this study. Additionally,
the shelter was informed of and gave consent for the use of
the dogs for research purposes before their arrival. Prior to
beginning the experiment, each dog had a complete blood count
(CBC) and serum chemistry analysis (IDEXX Laboratories, Inc.,
Westbrook, Maine) performed, along with physical evaluation by
the attending veterinarian and a fecal examination to rule out any
underlying disease that might preclude enrollment. Dogs were
excluded if they demonstrated serious behavioral issues, such as
human aggression that would endanger research personnel, were
severely emaciated, classified as a body condition score <3.5 on a
9-point scale (where one is emaciated and 9 is obese), or if their
initial evaluations revealed an underlying disease that required
more than routine treatments (such as heartworm positive dogs).
Dogs were individually housed in 1.2 × 1.8m cages within
one of two dog kennels at the LMU DeBusk Veterinary Teaching
Center. They were stratified by treatment and sex and evenly
distributed between the two kennels. Dogs were fed Purina Pro
Plan EN Gastroenteric Fiber Balance Dry Dog Food (Nestle
Purina, Inc., St. Louis, MO) to meet the daily metabolizable
energy requirements of neutered adult dogs at maintenance,
calculated as (70 ∗ BW0.75) ∗ 1.6 and split into two meals per
day. Body weight and body condition score (5-point scale) were
assessed weekly for the adjustment of diets. Dogs arrived from
the shelter and were started on the study diet more than 37 days
prior to starting treatments and 58 days before collecting samples
for this study.
Experimental Design and Treatments
These dogs were participating in a concurrent study evaluating
the impact of CBD on canine voluntary activity (20) with
treatments consisting of 0 (placebo treats; CON) or 75.6 ±
5.86mg CBD/d (CBD). Dogs were blocked by baseline activity
before being stratified by age, weight, and sex and randomly
assigned to treatments within each block. The CBD was a
constituent of a proprietary industrial hemp extract (AgTech
Scientific, Paris, KY) that was incorporated into treats and
administered in the form of 2 treats daily, each containing half
the daily dose. Both CON and CBD treats were composed of
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the following ingredients: chicken, chicken liver, Asian carp,
catfish, and in the case of the CBD treats, industrial hemp extract.
Cannabidiol was the primary constituent of the industrial hemp
extract; however, trace THC was present in the CBD treatment
(2.9± 0.22mg THC/d). Based on the mean BW of dogs included
in the study and analysis of the treats, mean dose of CBD ±
SD was 4.5 ± 0.77mg CBD/kg BW/d. Treats were offered solely
as a reward upon kennel re-entry following twice-daily exercise
within 30min of meals.
Blood Sample Collection
After 21 d of treatment administration, ∼6mL of blood was
collected via cephalic catheter or jugular venipuncture ∼2 h
after the final treat administration. The selection of this time
point was based on previous work demonstrating the half-
life of elimination of CBD to be between 1 and 4 h after oral
administration (21–23). Blood samples were collected into tubes
containing sodium heparin and were immediately centrifuged at
1,645 × g for 10min. Plasma was collected after centrifugation
then stored at−20◦C (<12 h) before long-term storage at−80◦C.
CIL/LC-MS-Based Untargeted
Metabolomics Analysis
Untargeted metabolomic profiling was done using a CIL/LC-
MS-based technique with an Agilent 1100 LC system (Palo
Alto, CA) connected to a Bruker Impact HD quadrupole
time-of-flight (QTOF) MS (Billerica, MA). This technique
uses a differential isotope labeling (12C and 13C-labeling) to
separate metabolites based on chemical groups followed by
LC-MS analysis (19). Detailed information regarding sample
preparation, labeling, normalization, LC-UV and LC-MS setup,
and metabolite quantification have been reported elsewhere (24,
25). Typical coefficient of variation for this high-performance
chemical isotope labeling LC-MS method for metabolome
analysis is in the range of 5–10% for individual metabolites
(26–28). In this study, amine/phenol- and carbonyl-containing
metabolites were analyzed. A total of 19 LC-MS data files were
generated (three quality control samples, eight CBD samples, and
eight CON samples).
Metabolite Data Processing
Raw data processing on the 19 LC-MS data files was performed
using ISOMS Pro 1.0 according to procedures described byMung
and Li (25). Peak pairs whose mean (sample) / mean (blank) was
≤ 4.0 were filtered out. Peak pairs with no data present in at
least 80% of the samples were filtered out. The final metabolite-
intensity table was generated using IsoMS-Quant (29).
Metabolite Identification
A two-tier identification approach was used to perform
metabolite identification. In tier 1, peak pairs were searched
against a chemical isotope-labeled metabolite library (CIL
Library) based on accurate mass and retention time (29). The
CIL Library contains 1,213 experimental entries, including 711
amines/phenols and 90 carbonyls. In tier 2, a linked identity
library (LI Library) was used for the identification of the
remaining peak pairs. The LI Library includes over 2,000 human
endogenous metabolites from 68 metabolic pathways, providing
high-confidence putative identification results based on accurate
mass and predicted retention time matches (30).
Statistical Analysis
The final metabolite intensity tables for the amine/phenol- and
carbonyl-containing metabolome were imported separately into
MetaboAnalyst 5.0 software package [www.metaboanalyst.ca;
(31)] for statistical analysis. Before statistical analysis, the data
were log-transformed, normalized by the median, and auto-
scaled. Median scaling was performed to eliminate unwanted
inter-sample variations to make the individual samples more
comparable to each other. Auto-scaling was used to make
the metabolites more comparable in magnitude to each other.
Univariate (volcano plot) and multivariate analysis (Partial
least squares discriminant analysis [PLS-DA] scores plot) were
then generated to identify overall treatment differences across
the multivariate dataset. The volcano plot was constructed by
plotting the fold change (FC; CBD/CON) of each metabolite
against its P-value. Metabolites with FC ≥ 1.2 or ≤ 0.83
having a false discovery ratio (FDR) ≤ 0.05 were considered
to be differentially increased or decreased relative to CON,
respectively. The utility of the metabolites with FC ≥ 1.2 or ≤
0.83 and FDR ≤ 0.05 to serve as potential biomarkers of the
effects of CBDwas tested using a receiver operating characteristic
(ROC) curves as calculated by the ROCCET web server using
MetaboAnalyst 5.0 software package. Metabolites with an area
under ROC (AUROC) ≥ 0.90 and a P ≤ 0.05 were considered
excellent biomarkers as defined in Xia et al. (17).
RESULTS
Amine/Phenol Metabolites
Within the amine/phenol analysis, a total of 2,681 unique peak
pairs (representing different compounds) were detected. Of those
peak pairs, 134 metabolites were positively identified in tier 1
(CIL Library; Supplementary Table 1) and 103 metabolites were
putatively identified with high confidence in tier 2 (LI Library;
Supplementary Table 2). The PLS-DA scores plot (Figure 1A)
shows a clear separation between CON and CBD samples, and
the permutation test (P < 0.01) confirms the validity of the
PLS-DA model (Supplementary Figure 1).
Volcano plot analysis showed that 32 metabolites
were differentially altered (FC ≥ 1.2 or ≤ 0.83, FDR
≤ 0.05) by CBD (Figure 1B; Table 1). Eighteen of those
metabolites—pyrimidodiazepine, 4-amino-4-deoxychorismate,




aminobutyraldehyde, 1,4-diaminobutane, tyramine, an
isomer of 2-deoxy-scyllo-inosamine, isoleucyl-alanine, 3-
(4-hydroxyphenyl)-pyruvate, aspartyl-threonine, vanillic
acid, and D-lysopine—were differentially increased (FC ≥
1.2, FDR ≤ 0.05) by CBD. The other 14 metabolites—N-
acetyl-L-asparagine, alanyl-proline, asparaginyl-aspartic acid,
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FIGURE 1 | (A) Partial least squares discriminant analysis (PLS-DA) scores plot and (B) volcano plot showing the differential amine/phenol-containing metabolites.
Fold change (FC) ≥ 1.2 (in red) or ≤ 0.83 (in blue) with false discovery ratio (FDR) ≤ 0.05 are differentially increased or reduced by cannabidiol (CBD) relative to
control (CON).




aminobutyric acid, and aspartyl-glutamine—were differentially
reduced (FC ≤ 0.83, FDR ≤ 0.05) by CBD compared to CON.
Univariate ROC analysis of the 32 identified amine/phenol-
containing metabolites that were differentially increased or







D-lysopine, o-tyrosine, phenylalanyl-glycine, 2,4-dihydroxyhept-
2-enedioate, asparaginyl-aspartic acid, isoferulic acid,
7-carboxy-7-carbaguanine, 3-(4-hydroxyphenyl)-pyruvate,
aspartyl-threonine, and isoleucyl-alanine—that appear to be
highly predictive of the metabolomic changes between CBD and
CON (AUROC≥ 0.90; P < 0.001; Figure 2).
Carbonyl Metabolites
Within the carbonyl analysis, a total of 612 unique peak pairs
were detected. Of those peak pairs, 6 peak pairs were positively
identified in tier 1 (CIL Library; Supplementary Table 1) and
15 peak pairs were putatively identified with high confidence in
tier 2 (LI Library; Supplementary Table 2). The PLS-DA scores
plot (Figure 3A) shows clear separation between CON and CBD
samples, and the permutation test (P< 0.01) confirms the validity
of the PLS-DA model (Supplementary Figure 2).
Volcano plot analysis showed that five metabolites were
differentially altered (FC ≥ 1.2 or ≤ 0.83, FDR ≤ 0.05) by
CBD (Figure 3B; Table 2). Glucose and 2-formylglutarate were
differentially increased (FC ≥ 1.2, FDR ≤ 0.05) by CBD, while
glyceraldehyde, isomer of glyceraldehyde, and 4-oxoglutaramate
were differentially reduced (FC ≤ 0.83, FDR ≤ 0.05) by CBD
compared to control.
Univariate ROC analysis of the five carbonyl metabolites
positively and putatively identified that were differentially altered
by CBD revealed that plasma glucose appears to be highly
predictive of the metabolomic changes between CBD and CON
(AUROC= 0.91; P = 0.020; Figure 4).
DISCUSSION
Amino Acid Metabolism
Increased concentrations of tyramine, 3-(4-hydroxyphenyl)-
pyruvate, 2,4-dihydroxyhept-2-enedioate, gamma-glutamyl-
gamma-aminobutyraldehyde, 1,4-diaminobutane, and
D-lysopine may indicate that CBD altered amino acid
metabolism. Tyramine, 3-(4-hydroxyphenyl)-pyruvate, and
2,4-dihydroxyhept-2-enedioate are intermediates in tyrosine and
phenylalanine metabolism (32–34). Tyramine, in particular, is
also involved in the biosynthesis of many secondary metabolites
in plants, such as isoquinoline alkaloids, flavonoids, and
hydroxycinnamic acid amines (35, 36). Gamma-glutamyl-
gamma-aminobutyraldehyde and 1,4-diaminobutane (i.e.,
putrescene) are intermediates in arginine, proline, and ornithine
degradation pathways (37, 38). Putrescene is also known to
play a role in the regulation of cell growth, protein synthesis,
apoptosis, and other cellular processes (39, 40). D-lysopine is an
amino opine derivative of L-lysine found in crown gall tumors
produced by pathogenic bacteria that infect plants, including C.
sativa. While not known to be produced in mammalian systems,
other opines like saccharopine are known intermediates in the
metabolism of lysine in mammals (41–43). The increase in these
metabolites may suggest that CBD enhanced degradation of
these amino acids.
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TABLE 1 | Identified amine/phenol-containing metabolites affected by cannabidiol (CBD) compared to control (CON).
Metabolite Normalized RTa FC FDR Identification levelb
Pyrimidodiazepine 1,029.2 2.89 0.002 Tier 2
4-Amino-4-deoxychorismate 504.2 2.38 0.004 Tier 2
Isoferulic acid 1,075.1 1.91 0.005 Tier 1
Isomer of D-Glucosamine 152.6 1.85 0.045 Tier 2
7-Carboxy-7-carbaguanine 369.6 1.64 0.019 Tier 2
2,4-Dihydroxyhept-2-enedioate 680.1 1.64 0.004 Tier 2
Ascorbate 530.4 1.62 0.023 Tier 2
2’-Deamino-2’-hydroxy-6’-dehydroparomamine 761.9 1.57 0.026 Tier 2
trans-2,3-Dihydroxycinnamate 856.8 1.53 0.001 Tier 2
gamma-Glutamyl-gamma-aminobutyraldehyde 337.7 1.52 0.010 Tier 2
1,4-Diaminobutane 1,281.7 1.50 0.007 Tier 1
Tyramine 1,538.7 1.50 0.007 Tier 1
Isomer of 2-Deoxy-scyllo-inosamine 208.1 1.47 0.031 Tier 2
Isoleucyl-Alanine 586.8 1.45 0.026 Tier 1
3-(4-Hydroxyphenyl)-pyruvate 1,068.7 1.31 0.019 Tier 2
Aspartyl-Threonine 236.0 1.31 0.019 Tier 1
Vanillic acid 1,026.1 1.26 0.012 Tier 1
D-Lysopine 999.8 1.20 0.019 Tier 2
N-Acetyl-L-Asparagine 492.6 0.83 0.023 Tier 2
Alanyl-Proline 477.2 0.82 0.026 Tier 1
Asparaginyl-Aspartic acid 149.6 0.79 0.026 Tier 1
Seryl-Aspartic acid 162.3 0.78 0.045 Tier 1
Phenylalanyl-Glycine 569.9 0.78 0.026 Tier 1
Prolyl-Glutamine 335.6 0.78 0.012 Tier 1
o-Tyrosine 1,313.2 0.77 0.023 Tier 1
N-Acetyl-L-Adrenaline 1,650.1 0.75 0.041 Tier 2
L-threo-3-Methylaspartate 491.9 0.74 0.045 Tier 2
Z-3-Peroxyaminoacrylate 666.3 0.72 0.024 Tier 2
L-Glutamate 5-semialdehyde 367.9 0.72 0.004 Tier 2
2-Methyl-3-hydroxy-5-formylpyridine-4-carboxylate 652.3 0.66 0.032 Tier 2
Aspartyl-Glutamine 194.8 0.65 0.001 Tier 1
Gamma-Aminobutyric acid 466.3 0.55 0.049 Tier 1
Metabolites with a fold change (FC) ≥ 1.2 relative to CON and a false discovery ratio (FDR) ≤ 0.05 were considered increased by CBD compared to CON. Metabolites with a FC ≤ 0.83
and an FDR ≤ 0.05 were considered reduced in CBD compared to CON.
aNormalized RT (retention time) shows the corrected retention time of the peak pair with Universal RT Calibrant data.
bTier 1 indicates positive metabolite identification within the chemical isotope labeling (CIL) metabolite library whereas Tier 2 indicates high confidence putative identification within the
linked identity (LI) library.
Decreased concentrations of N-acetyl-L-asparagine,
o-tyrosine, N-acetyl-L-adrenaline, L-threo-3-methylaspartate,
L-glutamate-5-semialdehyde, and 4-oxoglutaramate may also
suggest that CBD altered metabolism of other amino acids.
N-acetyl-L-asparagine is a derivative of asparagine that is
N-acetylated by N-acetyltransferase 1 (NAT1), one of several
acetyltransferases known to play a role in drug metabolism (44).
This enzyme has been suggested to play a role in the regulation
of mTOR complex I activation, cancer cell proliferation, and
mitochondrial function (44–46). As CBD is suspected to exert
anti-cancer effects, it may be prudent in future work to investigate
if CBD supplementation alters NAT1 activity. o-Tyrosine is a
structural isomer of tyrosine and a phenylalanine derivative.
It is considered a marker for oxidative stress as it is produced
through free-radical hydroxylation of phenylalanine (47, 48). If
the decrease in o-tyrosine was due to CBD supplementation, this
may contribute to the suspected antioxidative effects of CBD.
N-acetyl-L-adrenaline is a methylated form of epinephrine, an
adrenal hormone involved in the regulation of visceral functions
(49, 50).
L-threo-3-methylaspartate is an amino acid formed by
glutamate mutase and can be metabolized by methylaspartate
ammonia-lyase. It is found in the structures of the antibiotics
friulimicin and vicenistatin and in carbon metabolism of
haloarchaea (51, 52). L-glutamate-5-semialdehyde is a non-
proteinogenic amino acid that is an intermediate in both
proline and arginine biosynthesis from glutamate (53, 54).
4-oxoglutaramate is an intermediate in one of the histidine
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FIGURE 2 | Box and whisker plots for candidate amine/phenol-containing biomarkers altered by cannabidiol (CBD; in blue) compared to control (CON; in yellow).
Candidate amine/phenol biomarkers included (A) aspartyl-glutamine (AUROC = 1.00; P < 0.001); (B) gamma-aminobutyric acid (AUROC = 1.00; P = 0.005); (C)
gamma-glutamyl-gamma-aminobutyraldehyde (AUROC = 1.00; P < 0.001); (D) L-glutamate-5-semialdehyde (AUROC = 1.00; P < 0.001); (E) prolyl-glutamine
(AUROC = 1.00; P < 0.001); (F) pyrimidodiazepine (AUROC = 1.00; P < 0.001); (G) 4-amino-4-deoxychorismate (AUROC = 0.98; P < 0.001); (H)
trans-2,3-dihydroxycinnamate (AUROC = 0.98; P < 0.001); (I) alanyl-proline (AUROC = 0.97; P = 0.002); (J) N-acetyl-L-asparagine (AUROC = 0.97; P < 0.001); (K)
(Z)-3-peroxyaminoacrylate (AUROC = 0.95; P < 0.001); (L) 1,4-diaminobutane (AUROC = 0.95; P < 0.001); (M) 2’-deamino-2’-hydroxy-6’-dehydroparomamine
(Continued)
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FIGURE 2 | (AUROC = 0.95; P = 0.004); (N) ascorbate (AUROC = 0.95; P = 0.003); (O) D-lysopine (AUROC = 0.95; P = 0.004); (P) o-tyrosine (AUROC = 0.95;
P = 0.001); (Q) phenylalanyl-glycine (AUROC = 0.95; P = 0.002); (R) 2,4-dihydroxyhept-2-enedioate (AUROC = 0.94; P < 0.001); (S) asparaginyl-aspartic acid
(AUROC = 0.94; P = 0.003); (T) isoferulic acid (AUROC = 0.94; P < 0.001); (U) 7-carboxy-7-carbaguanine (AUROC = 0.92; P = 0.001); (V)
3-(4-hydroxyphenyl)pyruvate (AUROC = 0.91; P = 0.004); (W) aspartyl-threonine (AUROC = 0.91; P = 0.005); and (X) isoleucyl-alanine (AUROC = 0.91; P = 0.007).
FIGURE 3 | (A) Partial least squares discriminant analysis (PLS-DA) scores plot and (B) volcano plot showing the differential carbonyl-containing metabolites. Fold
change (FC) ≥ 1.2 (in red) or ≤ 0.83 (in blue) with false discovery ratio (FDR) ≤ 0.05 are differentially increased or reduced by cannabidiol (CBD) relative to
control (CON).
TABLE 2 | Identified carbonyl-containing metabolites affected by cannabidiol





2-Formylglutarate 569.3 1.99 0.021 Tier 2
Glucose 371.2 1.54 0.018 Tier 1
4-Oxoglutaramate 394.4 0.62 0.050 Tier 2
Isomer of Glyceraldehyde 471.1 0.42 0.035 Tier 1
Glyceraldehyde 453.2 0.38 0.040 Tier 1
Metabolites with a fold change (FC)≥ 1.2 relative to CON and a false discovery ratio (FDR)
≤ 0.05 considered increased in the CBD compared to CON. Metabolites with a FC≤ 0.83
and an FDR ≤ 0.05 considered reduced in CBD compared to CON.
aNormalized RT (retention time) shows the corrected retention time of the peak pair with
Universal RT Calibrant data.
bTier 1 indicates positive metabolite identification within the chemical isotope labeling (CIL)
metabolite library whereas Tier 2 indicates high confidence putative identification within
the linked identity (LI) library.
catabolism pathways that leads to the production of 2-
oxoglutarate (i.e., α-ketoglutarate), which then feeds into the
citric acid cycle (55, 56). Aspartyl-glutamine, aspartyl-threonine,
alanyl-proline, asparaginyl-aspartic acid, isoleucyl-alanine,
phenylalanyl-glycine, prolyl-glutamine, and seryl-glycine are
products of the incomplete breakdown of protein digestion
or catabolism. While some dipeptides are known to have
physiological or cell-signaling effects, none of the affected
dipeptides have been identified as one of these bioactive
molecules (57, 58).
FIGURE 4 | Box and whisker plot for candidate carbonyl-containing biomarker
altered by cannabidiol (CBD; in blue) compared to control (CON; in yellow).
Glucose (AUROC = 0.91; P = 0.020) was the only candidate biomarker for
carbonyl-containing metabolites.
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The altered concentrations of these metabolites suggest an
effect of CBD on amino acid metabolism. However, since the
relative concentrations of the individual amino acids (arginine,
aspartate, glutamate, and proline) were unaffected by treatment,
the biological significance of the changes in these metabolites is
unclear. Additional research is needed to assess the potential for
CBD to alter amino acid metabolism.
Glucose Metabolism
The increase in glucose, an isomer of glucosamine, 2′-deamino-
2′-hydroxy-6′-dehydroparomamine, and an isomer of 2-deoxy-
schyllo-inosamine may suggest that glucose metabolism was
altered by CBD. The endocannabinoid system—by which CBD
and other cannabinoids exert physiological effects—plays a well-
established role in glucose and energymetabolism,marking it as a
target for the treatment of metabolic diseases like type 2 diabetes
(59). Cannabinoids like CBD and THC have been suggested to
reduce hyperglycemia and increase insulin production in rodents
(60, 61), but this has yet to be investigated in a canine model.
Glucosamine is an amino sugar that is readily synthesized
in the body from glucose and glutamine. It is an essential
component of mucopolysaccharides that are incorporated into
connective tissue, mucous secretions, skin, tendons, ligaments,
and cartilage. Additionally, it helps regulate the synthesis of
collagen in cartilage (62–64). Because of its high concentration
in joint tissues, glucosamine is commonly used as a dietary
supplement in humans, horses, and dogs as a support for joint
health and function and to relieve symptoms of osteoarthritis,
though there is little scientific evidence supporting these
effects (65). Both 2-deoxy-scyllo-inosamine and 2’-deamino-
2’-hydroxy-6’-dehydroparomamine are intermediates in the
biosynthesis of aminoglycoside antibiotics, like kanamycin, from
glucose in Streptomyces bacterial species (66, 67). However, since
these metabolites are not known to be generated in mammalian
systems, the biological significance of this is unclear.
The decrease in gamma-aminobutyric acid (GABA),
glyceraldehyde, and an isomer of glyceraldehyde may also
indicate that CBD altered glucose metabolism. Best known as
the primary inhibitory neurotransmitter in the central nervous
system, GABA is also produced by insulin-producing β cells
of the pancreas and immune cells (68, 69). In the pancreas,
GABA inhibits glucagon secretion from neighboring α cells
and modulates glucose homeostasis (68, 70, 71). This action of
GABA in the pancreas has highlighted its potential as a target
for diabetes treatment (72). It has also been shown to regulate
cytokine secretion from human peripheral blood mononuclear
cells (PBMCs) and CD4+ T cells and is thought to exert
anti-inflammatory effects (73–75).
Glyceraldehyde, a triose monosaccharide, is an intermediate
in glycolysis in its phosphorylated form (GAP). Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), the enzyme that
catalyzes the conversion of GAP into 1,3-bisphosphoglycerate,
is a major regulator of carbon flux in the body (76). It is also
known to play a role in other cellular functions such as redox
sensing, membrane fusion, iron homeostasis, and cell death
(77). The decrease in glyceraldehyde may lend support to the
suspected anti-obesity and anti-diabetic effects of CBD; however,
the increase in glucose and decrease in GABA would appear to
be incongruous with this potential effect. These results highlight
a relatively unexplored avenue of CBD research that warrants
further investigation.
Hydroxycinnamic Acid Derivatives
The increase in plasma isoferulic acid (IFA), trans-2,3-
dihydroxycinnamate, and vanillic acid may suggest that CBD
altered the metabolism of hydroxycinnamic acid derivatives.
Isoferulic acid is a naturally occurring hydroxycinnamic acid
derivative commonly found in Lobelia and Cimicifuga species.
It is an isomer of ferulic acid, a phenolic compound that is a
component of lignin, which is commonly found in cell walls of
plants, including C. sativa (78). Ferulic acid has also been isolated
from hemp seed meal, a byproduct of hemp oil processing
(79). Both ferulic acid and IFA have been reported to have
anti-inflammatory, anti-viral, anti-oxidative, and anti-diabetic
properties and are commonly used as ingredients in herbal
medicines in Japan and China (80, 81). Isoferulic acid has been
shown to reduce plasma glucose in diabetic rats and to inhibit
IL-8 production in mice (82, 83). Additionally, IFA has been
suggested to act as an anti-glycation compound. Protein glycation
is a non-enzymatic reaction associated with oxidative stress and
reactive oxygen species (ROS) production; it is thought to be a
contributor to age-related diseases (84). In several studies, IFA
protected against fructose- and glucose-mediated glycation and
inhibited ROS production in vitro (80, 85). In humans, IFA has
been shown to be an intermediate in the metabolism of plant-
derived phenolic compounds like caffeic acid (86), with humans
obtaining the majority from dietary consumption.
Trans-2,3-dihydroxycinnamate is a derivative of cinnamic
acid, which is an intermediate in the biosynthesis of lignin,
flavonoids, and other secondary metabolites produced by plants
like C. sativa (87). Cinnamic acid and its derivatives, like trans-
2,3-dihydroxycinnamate, possess antioxidizing activity (88).
Vanillic acid is a dihydroxybenzoic acid derivative commonly
used as a flavoring agent. It is also an intermediate in the synthesis
of vanillin from ferulic acid and a phenolic compound that,
like IFA, is a component of lignin present in the secondary
cell wall of plants, including C. sativa (89, 90). Like other
lignin-associated aromatic acids, vanillic acid has been reported
to exert antimicrobial properties (91). If the increase in these
metabolites is a result of CBD supplementation, it is possible
that these compounds may contribute to the suspected anti-
microbial, anti-inflammatory, and antioxidative effects of hemp.
However, it is unlikely that the changes in these compounds are
solely due to increased dietary consumption as the treats used in
this study provided a small quantity of industrial hemp extract.
Conversely, it may be possible that changes in the metabolism
of these hydroxycinnamic acid derivatives occurred as a result of
CBD; additional work is warranted to further investigate these
potential effects.
Vitamin and Nucleotide Metabolism
Increased concentrations of pyrimidodiazepine, 4-amino-4-
deoxychorismate, 7-carboxy-7-carbaguanine, 2-formylglutarate,
and ascorbate may indicate an alteration of vitamin and
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nucleotide metabolism. Pyrimidodiazepine is a derivative of
uracil and a substrate for pyrimidodiazepine synthase, an enzyme
that can contribute to glutathione synthesis. Uracil derivatives
like pyrimidodiazepine are also thought to possess antimicrobial
and antioxidant properties (92). 4-amino-4-deoxychorismate is
a precursor for para-aminobenzoic acid (pABA) biosynthesis,
which is a precursor for folic acid (vitamin B9) synthesis in plants
and microorganisms (93, 94). While vitamin B9 is an essential
cofactor that facilitates methyl transfers, mammals do not possess
the enzymes to produce folic acid and instead rely on dietary
consumption of the vitamin (93). 7-carboxy-7-carbaguanine
is pyrrolopyrimidine that, like 4-amino-4-deoxychorismate, is
involved in the biosynthesis of vitamin B9 (95). 2-formylglutarate
is an intermediate in nicotinamide metabolism in several
bacterial species [(96, 97)]. Ascorbate, or vitamin C, can be
synthesized in dogs from glucose or ingested in the diet
(98, 99). Vitamin C serves as a cofactor in several essential
reactions, including collagen synthesis and wound healing, as
well as an antioxidant. If the increase in ascorbate was due
to CBD supplementation, this may contribute to the suspected
antioxidative effects of CBD.
Decreased concentrations of 2-methyl-3-hydroxy-5-
formylpyridine-4-carboxylate and (Z)-3-peroxyaminoacrylate
may also support an effect of CBD on vitamin and nucleotide
metabolism. 2-methyl-3-hydroxy-5-formylpyridine-4-
carboxylate is an intermediate in the pyridoxine (vitamin
B6) degradation pathway (100). Vitamin B6 is an essential
cofactor in several enzymatic reactions, including the
synthesis of glutathione, an important antioxidant (101).
(Z)-3-peroxyaminoacrylate is an intermediate in bacterial
pyrimidine degradation pathway known as the Rut pathway.
However, this pathway and intermediate are not known to play a
role in mammalian pyrimidine metabolism (102).
Since the relative concentrations of pyridoxine, uracil, and
folate were not affected by treatment, and since several of
these metabolites are not known to be generated in mammalian
systems, the biological significance of these changes is unclear.
However, increased pyrimidodiazepine and ascorbate, along with
decreased 2-methyl-3-hydroxy-5-formylpyridine-4-carboxylate,
may indicate an influence of CBD on antioxidant status. Further
studies are needed to determine the roles of these metabolites and
the potential effects of CBD on these pathways.
Strengths and Limitations
Cannabidiol is already being supplemented to dogs for
its potential therapeutic applications including osteoarthritis,
separation anxiety, noise phobias, and epilepsy (4, 11). Several
studies have evaluated its effectiveness in dogs with osteoarthritis
(23, 103, 104) noise phobias (105), and epilepsy (106) with mixed
results. Considerable work has also been done investigating
pharmacokinetics (21–23, 107) and safety (108, 109) following
oral CBD administration; however, this study is the first
to evaluate the impact of CBD supplementation on the
canine metabolome. This analysis provides a comprehensive
scan of potential metabolic targets in dogs receiving CBD;
however, because of the lack of metabolic profile with CBD
it was not intended to be all-encompassing but rather a first
look into the potential for CBD supplementation to alter
the canine metabolome. Thus, this study may be limited
by the relatively short duration of CBD supplementation,
small sample size, lack of baseline measurement, and the
use of only a single CBD dosage. Even so, identifying
changes in the metabolome is essential for directing future
targeted investigations into both the physiological relevance
of these changes as well as elucidating potential mechanisms
leading to these observed effects. It would be beneficial
for future work to evaluate metabolomic changes in an
unhealthy or diseased population of dogs supplemented with
CBD and potential differences between acute and long-term
CBD administration.
CONCLUSIONS
This study demonstrated the canine metabolome was altered
with 4.5mg CBD/kg BW/d supplementation for 3 weeks. Altered
metabolites may suggest a potential for CBD to influence glucose,
amino acid, vitamin, and nucleotide metabolism. Additionally,
the increase in relative concentrations of metabolites like
o-tyrosine, IFA, glucosamine, and pyrimidodiazepine may
indicate potential pathways by which CBD may exert suspected
anti-inflammatory, antioxidant, and antimicrobial effects.
Several metabolites were identified as potential biomarkers
for changes in the canine metabolome by CBD. Further
studies with larger sample sizes, longer supplementation
periods and baseline comparisons to refine metabolites
are necessary to elucidate the physiological relevance of
these changes.
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